Edward Pershing - Nov 22, 2024 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Role
CEO, Director
Signature
/s/ Edward Pershing
Stock symbol
PVCT
Transactions as of
Nov 22, 2024
Transactions value $
$230,005
Form type
4
Date filed
11/25/2024, 05:12 PM
Previous filing
Oct 17, 2024
Next filing
Dec 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PVCT Series D-1 Convertible Preferred Stock Purchase $230K +80.4K +4.99% $2.86* 1.69M Nov 22, 2024 Common Stock 804K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired 80,365 shares of Series D-1 Preferred Stock in a private transaction for $230,000.
F2 Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
F3 The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.